FEATURE_phases list | FEATURE_enrollmentCount int64 | FEATURE_allocation string | FEATURE_interventionModel string | FEATURE_primaryPurpose class label | FEATURE_masking class label | FEATURE_healthyVolunteers bool | FEATURE_sex class label | FEATURE_oversightHasDmc bool | FEATURE_briefSummary string | FEATURE_detailedDescription string | FEATURE_conditions string | FEATURE_conditionsKeywords string | FEATURE_protocolPdfText string | FEATURE_numArms int64 | FEATURE_armDescriptions string | FEATURE_armGroupTypes list | FEATURE_numInterventions int64 | FEATURE_interventionTypes list | FEATURE_interventionDescriptions string | FEATURE_interventionNames string | FEATURE_numLocations int64 | FEATURE_locationDetails string | LABEL_ct_level_ade_population int64 | LABEL_sum_dosing_errors int64 | LABEL_dosing_error_rate float32 | LABEL_wilson_label int64 | METADATA_nctId string | METADATA_overallStatus class label | METADATA_completionDate date32 | METADATA_startDate date32 | METADATA_leadSponsorName string | METADATA_leadSponsorClass class label | METADATA_hasProtocol bool | METADATA_hasSap bool | METADATA_hasIcf bool | METADATA_protocolPdfLinks string | METADATA_count_Accidental drug intake by child int64 | METADATA_count_Accidental overdose int64 | METADATA_count_Accidental overdose (therapeutic agent) int64 | METADATA_count_Accidental underdose int64 | METADATA_count_Deliberate overdose int64 | METADATA_count_Dose calculation error int64 | METADATA_count_Drug administration error int64 | METADATA_count_Drug overdose int64 | METADATA_count_Drug overdose accidental int64 | METADATA_count_Extra dose administered int64 | METADATA_count_Incorrect dosage administered int64 | METADATA_count_Incorrect dose administered int64 | METADATA_count_Incorrect drug administration duration int64 | METADATA_count_Incorrect drug administration rate int64 | METADATA_count_Incorrect product administration duration int64 | METADATA_count_Intentional overdose int64 | METADATA_count_Medication error int64 | METADATA_count_Medication monitoring error int64 | METADATA_count_Multiple drug overdose int64 | METADATA_count_Multiple drug overdose accidental int64 | METADATA_count_Multiple drug overdose intentional int64 | METADATA_count_Multiple use of single-use product int64 | METADATA_count_Non-accidental overdose int64 | METADATA_count_Overdose int64 | METADATA_count_Overdose NOS int64 | METADATA_count_Overmedication int64 | METADATA_count_Prescribed overdose int64 | METADATA_count_Treatment noncompliance int64 | METADATA_count_Underdose int64 | METADATA_count_Unintentional medical device removal int64 | METADATA_count_Unintentional medical device removal by patient int64 | METADATA_wilson_lower_bound float32 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[
5
] | 128 | NA | SINGLE_GROUP | 4SUPPORTIVE_CARE | 0NONE | true | 0ALL | false | This study examined the possible sensitization and irritation effects of a moisturizer with sunscreen SPF 50+. | The design for this study is standard for human repeat insult patch tests. To test the moisturizer with sunscreen SPF 50+ for the potential to induce contact sensitization by repetitive applications, healthy subjects received 9 applications at 48 to 72 hour intervals of the moisturizer to the upper back. Patches were r... | Skin Irritation | Cetaphil Daily Facial Moisturizer with SPF 50+ Hypoallergenicity Skin Irritation | null | 1 | arm 1: All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+ | [
0
] | 1 | [
0
] | intervention 1: All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+ | intervention 1: Facial Moisturizer with SPF 50+ | 1 | Colorado Springs | Colorado | United States | -104.82136 | 38.83388 | 110 | 0 | 0 | 0 | NCT01892657 | 1COMPLETED | 2008-08-01 | 2008-03-01 | Galderma R&D | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 11 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | false | 0ALL | false | This study will evaluate the safety and side effects of two experimental vaccines in patients with kidney cancer and determine whether the vaccines "turn on" an immune response to the cancer. Each vaccine contains one of two peptides (pieces of proteins) from the fibroblast growth factor 5 (FGF-5) antigen, a protein pr... | Background:
Several preliminary clinical results in the treatment of cancer lend credence to the hypothesis that augmented T-cell responses will improve IL-2 therapy. A peptide vaccine derived from the melanoma/melanosomal antigen, GP100, when given with high-dose IL-2 resulted in a response rate over 30% in a small P... | Kidney Cancer | Clinical Response Toxicity Immunologic Response Adjuvant IL-2 Renal Cancer | null | 3 | arm 1: Patients who do not need or are ineligible for treatment with interleukin-2 (IL-2) and patients who have previously had IL-2 therapy.
A3 FGF-5 (Fibroblast growth factor 5): 172-176/217-220 peptide - two 1 ml injections in the anterior thigh deep subcutaneous tissue within 2c of each other. arm 2: Patients who r... | [
0,
0,
0
] | 3 | [
0,
0,
10
] | intervention 1: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other. intervention 2: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other. intervention 3: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on t... | intervention 1: 117-126:Fibroblast growth factor 5 (FGF-5) intervention 2: Fibroblast growth factor 5 (FGF-5):172-176/217-220 intervention 3: IL-2 | 1 | Bethesda | Maryland | United States | -77.10026 | 38.98067 | 11 | 0 | 0 | 0 | NCT00089778 | 6TERMINATED | 2008-08-05 | 2004-09-10 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 83 | RANDOMIZED | CROSSOVER | 7BASIC_SCIENCE | 4QUADRUPLE | true | 0ALL | null | To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females | null | Healthy Volunteers | QT/QTc | null | 3 | arm 1: None arm 2: None arm 3: None | [
0,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6. intervention 2: Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6. intervention 3: Subjects will receive placebo ... | intervention 1: immediate release guanfacine hydrochloride intervention 2: moxifloxacin intervention 3: Placebo | 1 | Tacoma | Washington | United States | -122.44429 | 47.25288 | 216 | 0 | 0 | 0 | NCT00672984 | 1COMPLETED | 2008-08-07 | 2008-04-18 | Shire | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 526 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries relative to placebo. | null | Insomnia | null | 4 | arm 1: Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks arm 2: Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks arm 3: Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks arm 4: Placebo to esmirtazapine | [
0,
0,
0,
2
] | 2 | [
0,
0
] | intervention 1: Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohy... | intervention 1: Esmirtazapine intervention 2: Placebo | 0 | null | 1,050 | 0 | 0 | 0 | NCT00482612 | 1COMPLETED | 2008-08-11 | 2006-12-07 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 299 | RANDOMIZED | PARALLEL | 1PREVENTION | 2DOUBLE | false | 0ALL | true | The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE). | null | Hepatic Encephalopathy | null | 2 | arm 1: Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation. arm 2: Participants were administered a single matching placebo tablet 2 times p... | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Oral intervention 2: Oral | intervention 1: Rifaximin intervention 2: Placebo | 0 | null | 299 | 0 | 0 | 0 | NCT00298038 | 1COMPLETED | 2008-08-15 | 2005-12-19 | Bausch Health Americas, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 14 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion; in t... | null | Alzheimer's Disease | Functional magnetic resonance imaging examination Alzheimer's Disease Donepezil hydrochloride Aricept | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks | intervention 1: Donepezil hydrochloride | 1 | Milwaukee | Wisconsin | United States | -87.90647 | 43.0389 | 14 | 0 | 0 | 0 | NCT00477659 | 1COMPLETED | 2008-08-15 | 2007-07-23 | Eisai Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 126 | NON_RANDOMIZED | null | 0TREATMENT | 0NONE | false | 0ALL | false | To evaluate the safety of the long-term use of pregabalin. | null | Neuralgia, Postherpetic | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks | intervention 1: pregabalin | 33 | Nagoya | Aichi-ken | Japan | 136.90641 | 35.18147
Urayasu | Chiba | Japan | 139.90055 | 35.65879
Kasuya-gun | Fukuoka | Japan | N/A | N/A
Maebashi | Gunma | Japan | 139.08333 | 36.4
Takasaki | Gunma | Japan | 139.01667 | 36.33333
Asahikawa | Hokkaido | Japan | 142.36489 | 43.77063
Asahikawa | Hokkaido | Japan | 142.364... | 126 | 0 | 0 | 0 | NCT00424372 | 1COMPLETED | 2008-08-19 | 2007-01-12 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 629 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD). | The primary objective of this pivotal study is to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). The cure rates at end of therapy and recurrence rates will be evaluated and compared. | Clostridium Infections Diarrhea | CDAD, Clostridium difficile, diarrhea Clostridium difficile-Associated Diarrhea | null | 2 | arm 1: Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours \[q12h\] regimen) with intermittent matching placebo to fidaxomicin arm 2: Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours \[q6h\] regimen). | [
0,
1
] | 3 | [
0,
0,
0
] | intervention 1: 200 mg oral capsules two times daily (q12h regimen) intervention 2: 125 mg capsules q6hr (4 times a day) intervention 3: Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing) | intervention 1: Fidaxomicin intervention 2: Vancomycin intervention 3: Matching Placebo to Fidaxomicin | 0 | null | 623 | 1 | 0.001605 | 1 | NCT00314951 | 1COMPLETED | 2008-08-21 | 2006-05-02 | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000283 |
[
3,
4
] | 262 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab compared with placebo when combined with a single stable background immunosuppressive medication in subjects with moderate to severe systemic lupus erythematosus (SLE). The primary ef... | null | Lupus Erythematosus, Systemic | Rituxan SLE Lupus | null | 2 | arm 1: Participants will receive rituximab 1000 mg intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 100... | [
0,
2
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: Rituximab will be supplied as a sterile liquid for IV administration. intervention 2: Placebo will be supplied as a sterile liquid for IV administration. intervention 3: None intervention 4: None intervention 5: None | intervention 1: Rituximab intervention 2: Placebo intervention 3: Prednisone intervention 4: Acetaminophen intervention 5: Diphenhydramine | 65 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Huntsville | Alabama | United States | -86.58594 | 34.7304
Paradise Valley | Arizona | United States | -111.94265 | 33.53115
La Jolla | California | United States | -117.2742 | 32.84727
Los Angeles | California | United States | -118.24368 | 34.05223
Los Angel... | 257 | 0 | 0 | 0 | NCT00137969 | 1COMPLETED | 2008-08-25 | 2005-05-10 | Genentech, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 14 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque macrophage content when compared to placebo (an approximate decrease of up to 30% is expected). | null | Peripheral Vascular Diseases | null | 2 | arm 1: Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks arm 2: Participants will be orally administered placebo once daily for 12 weeks. | [
0,
2
] | 2 | [
0,
0
] | intervention 1: MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks. intervention 2: Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks. | intervention 1: MK-0736 intervention 2: Comparator: placebo (unspecified) | 0 | null | 14 | 4 | 0.285714 | 1 | NCT00679055 | 6TERMINATED | 2008-08-26 | 2007-03-31 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.117214 | |
[
3
] | 27 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic myeloid leukemia who are in accelerated phase or blast phase (blast crisis) with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors | study was designed to assess the hematologic response associated with treatment of oral panobinostat. Hematologic response is defined as the overall of complete hematologic response (CHR), and of no evidence of leukemia (NEL) and of the return to chronic phase (RTC). Hematologic responses were to be confirmed after 4 w... | Leukemia, Myeloid, Chronic | Refractory Chronic Myeloid Leukemia accelerated phase blast phase (blast crisis) adults oral LBH589 | null | 1 | arm 1: Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat was administered at the same time each morning, and with an 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed)... | [
0
] | 1 | [
0
] | intervention 1: None | intervention 1: LBH589 | 26 | Duarte | California | United States | -117.97729 | 34.13945
Aurora | Colorado | United States | -104.83192 | 39.72943
Denver | Colorado | United States | -104.9847 | 39.73915
Chicago | Illinois | United States | -87.65005 | 41.85003
Chicago | Illinois | United States | -87.65005 | 41.85003
Chicago | Illinois | United S... | 27 | 0 | 0 | 0 | NCT00449761 | 6TERMINATED | 2008-08-26 | 2007-02-23 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 339 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients. Safety of Duloxetine will also be assessed. | null | Depressive Disorder, Major | null | 2 | arm 1: Duloxetine 60 mg arm 2: Duloxetine 120 mg | [
0,
0
] | 2 | [
0,
0
] | intervention 1: Capsule intervention 2: Capsule | intervention 1: Duloxetine intervention 2: Placebo | 0 | null | 338 | 0 | 0 | 0 | NCT02229825 | 1COMPLETED | 2008-08-26 | 2007-02-09 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 72 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Participants invited to take part have metastatic cancer of the esophagus (gullet) or stomach. | null | Esophageal Cancer Gastric Cancer | Esophagus Gastric Adenocarcinoma EGFR matuzumab EMD 72000 randomized Epirubicin cisplatin capecitabine Metastatic Esophago-Gastric cancer | null | 2 | arm 1: None arm 2: None | [
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn. intervention 2: Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a max... | intervention 1: Matuzumab intervention 2: Epirubicin intervention 3: Cisplatin intervention 4: Capecitabine | 22 | Essen | N/A | Germany | 7.01228 | 51.45657
Hamburg | N/A | Germany | 9.99302 | 53.55073
Oldenburg | N/A | Germany | 8.21467 | 53.14118
Recklinghausen | N/A | Germany | 7.19738 | 51.61379
A Coruña | N/A | Spain | -8.396 | 43.37135
Barcelona | N/A | Spain | 2.15899 | 41.38879
Cadiz | N/A | Spain | -6.2891 | 36.52672
Vale... | 71 | 0 | 0 | 0 | NCT00215644 | 1COMPLETED | 2008-08-31 | 2005-08-31 | Merck KGaA, Darmstadt, Germany | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 17,802 | RANDOMIZED | PARALLEL | 1PREVENTION | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events. | AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascula... | Elevated High-sensitivity C-Reactive Protein (hsCRP) | Primary prevention Cardiovascular disease Statin therapy C-reactive protein | null | 2 | arm 1: Rosuvastatin 20 mg once daily arm 2: Placebo once daily | [
0,
2
] | 2 | [
0,
10
] | intervention 1: Oral intervention 2: Oral | intervention 1: Rosuvastatin intervention 2: Placebo | 856 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Calera | Alabama | United States | -86.7536 | 33.1029
Columbiana | Alabama | United States | -86.60721 | 33.17817
Decatur | Alabama | United States | -86.98334 | 34.60593
Graysville | Alabama | United States | -86.97138 | 33.62066
Haleyville | Alabama | United... | 17,733 | 1 | 0.000056 | 0 | NCT00239681 | 6TERMINATED | 2008-09-01 | 2003-02-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.00001 |
[
4
] | 1,083 | RANDOMIZED | PARALLEL | 1PREVENTION | 2DOUBLE | false | 1FEMALE | false | The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women. | null | Endometrial Hyperplasia Osteoporosis | Endometrium Uterus Menopause | null | 4 | arm 1: BZA 20mg/CE 0.625 arm 2: BZA 20mg/CE 0.45 arm 3: CE 0.45mg/MPA1.5mg arm 4: Placebo | [
0,
0,
1,
2
] | 4 | [
0,
0,
0,
10
] | intervention 1: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study. intervention 2: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study. intervention 3: Subjec... | intervention 1: Bazedoxifene/Conjugated Estrogen intervention 2: Bazedoxifene/Conjugated Estrogen intervention 3: CE 0.45 mg/MPA 1.5mg intervention 4: Placebo | 9 | Upland | California | United States | -117.64839 | 34.09751
Inverness | Florida | United States | -82.33037 | 28.83582
West Palm Beach | Florida | United States | -80.05337 | 26.71534
Decatur | Georgia | United States | -84.29631 | 33.77483
Honolulu | Hawaii | United States | -157.85833 | 21.30694
Lexington | Kentucky ... | 1,061 | 5 | 0.004713 | 1 | NCT00242710 | 1COMPLETED | 2008-09-01 | 2005-09-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.002015 |
[
5
] | 550 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI). | null | Skin Diseases, Bacterial | skin infection antibiotics | null | 2 | arm 1: Arm 1: Tigecycline arm 2: Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours) intervention 2: Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 ... | intervention 1: Tigecycline intervention 2: ampicillin-sulbactam | 57 | Scottsdale | Arizona | United States | -111.89903 | 33.50921
Jonesboro | Arkansas | United States | -90.70428 | 35.8423
Chula Vista | California | United States | -117.0842 | 32.64005
Mission Viejo | California | United States | -117.672 | 33.60002
National City | California | United States | -117.0992 | 32.67811
Denve... | 531 | 1 | 0.001883 | 1 | NCT00368537 | 1COMPLETED | 2008-09-01 | 2006-09-01 | Wyeth is now a wholly owned subsidiary of Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000333 |
[
0
] | 853 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a Genen... | null | Choroidal Neovascularization, Age-related Macular Degeneration | CNV Lucentis AMD Age-related macular degeneration RVO | null | 1 | arm 1: Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment. | [
0
] | 1 | [
0
] | intervention 1: Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) | intervention 1: Ranibizumab 0.5 mg | 0 | null | 790 | 3 | 0.003797 | 1 | NCT00379795 | 1COMPLETED | 2008-09-01 | 2005-04-01 | Genentech, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001292 |
[
4
] | 116 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Octagam is a solvent/detergent-treated human normal immunoglobulin (IGIV) solution for intravenous administration. Octagam 5% is currently registered in about 80 countries. This study evaluated the efficacy and safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura (ITP) in adults. As Octagam 10% is essentially s... | The primary objective of the study was to investigate the efficacy of Octagam® 10% in correcting platelet count. The blood count as well as laboratory chemistry were checked repeatedly up to day 21.
The secondary objective of the study was to investigate the safety of Octagam® 10%. Safety was assessed by monitoring vi... | Immune Thrombocytopenic Purpura | null | 1 | arm 1: Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days. | [
0
] | 1 | [
0
] | intervention 1: Octagam 10% was supplied as a ready-to-use solution in glass bottles. | intervention 1: Octagam 10% | 1 | Vienna | N/A | Austria | 16.37208 | 48.20849 | 116 | 1 | 0.008621 | 1 | NCT00426270 | 1COMPLETED | 2008-09-01 | 2006-06-01 | Octapharma | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001523 | |
[
4
] | 348 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This trial is conducted in Europe.
The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir. You will be treated with either insulin detemir or NPH insulin once or twice daily as basal insulin. Additionally you will receive insulin aspart as bolus insulin | null | Diabetes Diabetes Mellitus, Type 1 | null | 2 | arm 1: insulin detemir + insulin aspart arm 2: NPH insulin + insulin aspart | [
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: s.c. injection, once or twice daily. intervention 2: s.c. injection, once or twice daily. intervention 3: s.c. injection, at main meals. | intervention 1: insulin detemir intervention 2: insulin NPH intervention 3: insulin aspart | 43 | Pleven | N/A | Bulgaria | 24.61667 | 43.41667
Sofia | N/A | Bulgaria | 23.32415 | 42.69751
Varna | N/A | Bulgaria | 27.91667 | 43.21667
Olomouc | N/A | Czechia | 17.25175 | 49.59552
Pardubice | N/A | Czechia | 15.77659 | 50.04075
Prague | N/A | Czechia | 14.42076 | 50.08804
Glostrup Municipality | N/A | Denmark | 12.40... | 347 | 1 | 0.002882 | 1 | NCT00435019 | 1COMPLETED | 2008-09-01 | 2007-02-01 | Novo Nordisk A/S | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000509 | |
[
3
] | 50 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to understand the safety and tolerability of INCB018424 in patients with rheumatoid arthritis | null | Rheumatoid Arthritis | Rheumatoid arthritis | null | 5 | arm 1: INCB018424 15 mg twice daily (BID) or matching placebo arm 2: INCB018424 5 mg BID or matching placebo arm 3: INCB018424 25 mg BID or matching placebo arm 4: INCB018424 50 mg once daily (QD) or matching placebo arm 5: Matching placebo, oral | [
0,
0,
0,
0,
2
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: INCB018424 intervention 2: Placebo | 15 | Huntsville | Alabama | United States | -86.58594 | 34.7304
Upland | California | United States | -117.64839 | 34.09751
Gainesville | Florida | United States | -82.32483 | 29.65163
Palm Harbor | Florida | United States | -82.76371 | 28.07807
Kalispell | Montana | United States | -114.31291 | 48.19579
Hickory | North Car... | 50 | 1 | 0.02 | 1 | NCT00550043 | 1COMPLETED | 2008-09-01 | 2007-10-01 | Incyte Corporation | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.003539 |
[
2
] | 104 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain. | null | Neuralgia, Postherpetic Diabetic Neuropathy Painful Small-Fiber Neuropathy Idiopathic Distal Sensory Polyneuropathy | null | 2 | arm 1: Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period. arm 2: Patients in Group B will be treated with placebo. | [
1,
2
] | 2 | [
0,
0
] | intervention 1: pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks intervention 2: pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks | intervention 1: Comparator: pregabalin intervention 2: Comparator: Placebo (unspecified) | 0 | null | 104 | 1 | 0.009615 | 1 | NCT00570310 | 1COMPLETED | 2008-09-01 | 2007-12-01 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001699 | |
[
4
] | 649 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy. The anticipated time of study treatment is 1-2 years, and the target sample size is greater t... | null | Renal Cell Cancer | null | 2 | arm 1: Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units... | [
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: 10 mg/kg IV every 2 weeks intervention 2: 9 MIU SC 3 times/week intervention 3: IV every 2 weeks | intervention 1: Bevacizumab [Avastin] intervention 2: Interferon alfa 2a [Roferon] intervention 3: Placebo | 104 | Adelaide | N/A | Australia | 138.59863 | -34.92866
Adelaide | N/A | Australia | 138.59863 | -34.92866
Brisbane | N/A | Australia | 153.02809 | -27.46794
Canberra | N/A | Australia | 149.12807 | -35.28346
Frankston | N/A | Australia | 145.12291 | -38.14458
Kurralta Park | N/A | Australia | 138.56702 | -34.95142
Melbourn... | 641 | 1 | 0.00156 | 1 | NCT00738530 | 1COMPLETED | 2008-09-01 | 2004-06-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.000275 | |
[
3
] | 42 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This is a single arm study.
The tumor specimen is analyzed for the presence of a fusion protein which corresponds to available peptides. Patients undergo T cell harvest 10 days after an initial priming peptide-pulsed antigen presenting cell (APC) vaccine is performed.
Fresh APCs are utilized for initial priming vacci... | Eradication of low tumor burdens can occur in vivo when T-cell mediated responses are generated against specific tumor antigens. The Ewing's sarcoma family of tumors (ESFT) and alveolar rhabdomyosarcoma (AR) display several features which make them candidate diseases for trials of such immunotherapy. First, intensive c... | Ewing's Sarcoma Rhabdomyosarcoma | Rhabdomyosarcoma Ewing's Sarcoma Immunotherapy Tumor Vaccine Interleukin-2 | null | 1 | arm 1: Patients receive oral indinavir sulfate 350 mg/m\^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10\^6 injection; harvested autologous T cells (minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 min... | [
0
] | 3 | [
2,
0,
3
] | intervention 1: 3 syringes containing 1 x 10\^6peptide pulsed dendritic cells intervention 2: Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours. intervention 3: Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequen... | intervention 1: therapeutic autologous dendritic cells intervention 2: indinavir sulfate intervention 3: peripheral blood stem cell transplantation | 1 | Bethesda | Maryland | United States | -77.10026 | 38.98067 | 42 | 0 | 0 | 0 | NCT00001566 | 1COMPLETED | 2008-09-01 | 1996-12-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 55 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma). | null | Non-Hodgkin's Lymphoma | null | 1 | arm 1: 500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles | [
0
] | 1 | [
0
] | intervention 1: 500 mg, oral, QD, up to six 28 day cycles | intervention 1: LY317615 | 3 | Royal Oak | Michigan | United States | -83.14465 | 42.48948
Minneapolis | Minnesota | United States | -93.26384 | 44.97997
Rochester | Minnesota | United States | -92.4699 | 44.02163 | 55 | 0 | 0 | 0 | NCT00042666 | 1COMPLETED | 2008-09-01 | 2002-06-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 630 | null | PARALLEL | 0TREATMENT | null | false | 0ALL | null | Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients. | null | HIV Infections | null | 2 | arm 1: None arm 2: None | [
5,
5
] | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: Tipranavir intervention 2: Ritonavir(r) intervention 3: Comparator Protease Inhibitor (CPI) | 117 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Tucson | Arizona | United States | -110.92648 | 32.22174
Berkeley | California | United States | -122.27275 | 37.87159
Beverly Hills | California | United States | -118.40036 | 34.07362
Fountain Valley | California | United States | -117.95367 | 33.70918
Long Be... | 620 | 0 | 0 | 0 | NCT00054717 | 1COMPLETED | 2008-09-01 | 2003-01-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 106 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma | null | Carcinoma, Renal Cell | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: 50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity | intervention 1: SU011248 | 15 | Duarte | California | United States | -117.97729 | 34.13945
Pasadena | California | United States | -118.14452 | 34.14778
San Francisco | California | United States | -122.41942 | 37.77493
Boston | Massachusetts | United States | -71.05977 | 42.35843
Boston | Massachusetts | United States | -71.05977 | 42.35843
Boston ... | 106 | 0 | 0 | 0 | NCT00077974 | 1COMPLETED | 2008-09-01 | 2004-02-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3,
4
] | 469 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | This study will examine the effect of antidepressant medication on rates of death and disease in depressed people with chronic heart failure. | Comorbid depression in people with chronic medical illness is a serious public health concern. Depressive disorders lead to increased morbidity, mortality, and poorer outcomes in ischemic heart disease, a leading cause of chronic heart failure (CHF). Evidence suggests that a relationship exists between depression and C... | Heart Failure, Congestive Chronic Heart Failure Depression | Antidepressive Agents | null | 2 | arm 1: Participants will take sertraline for 12 weeks arm 2: Participants will take placebo for 12 weeks | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Dosage ranging from 50 mg to 200 mg once a day intervention 2: Dosage ranging from 50 mg to 200 mg once a day | intervention 1: Sertraline intervention 2: Placebo | 1 | Durham | North Carolina | United States | -78.89862 | 35.99403 | 469 | 0 | 0 | 0 | NCT00078286 | 1COMPLETED | 2008-09-01 | 2003-11-01 | Duke University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 170 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first... | Approximately one-third of the world's population is infected with Mycoplasma tuberculosis; 7 to 8 million new cases of active TB occur each year. TB is the second most common infectious cause of death worldwide. Appropriate treatment of persons with active TB is very important in limiting the transmission of M. tuberc... | Tuberculosis | null | 2 | arm 1: INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks arm 2: INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks | [
0,
2
] | 1 | [
0
] | intervention 1: 400mg daily for 8 weeks | intervention 1: Moxifloxacin | 1 | Rio de Janeiro | Rio de Janeiro | Brazil | -43.18223 | -22.90642 | 146 | 0 | 0 | 0 | NCT00082173 | 1COMPLETED | 2008-09-01 | 2004-10-01 | Johns Hopkins University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 33 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | This phase II trial is studying how well giving tipifarnib together with fulvestrant works as second-line therapy in treating postmenopausal women with hormone receptor-positive inoperable locally advanced or metastatic breast cancer that has progressed after previous first-line endocrine therapy. Tipifarnib may stop t... | PRIMARY OBJECTIVES:
I. To determine the efficacy of tipifarnib (R115777, Zarnestra™) in combination with fulvestrant based on clinical benefit rate (CBR, a combination of complete response rate, partial response rate, and stable disease for more than 24 weeks) in postmenopausal women with hormone receptor-positive met... | Estrogen Receptor-positive Breast Cancer Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer | null | 1 | arm 1: Patients receive fulvestrant intramuscularly on day 1 and oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity\*. | [
0
] | 2 | [
0,
0
] | intervention 1: Given intramuscularly intervention 2: Given IV | intervention 1: fulvestrant intervention 2: tipifarnib | 1 | The Bronx | New York | United States | -73.86641 | 40.84985 | 33 | 0 | 0 | 0 | NCT00082810 | 1COMPLETED | 2008-09-01 | 2004-03-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 750 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC). | null | Carcinoma, Renal Cell | null | 2 | arm 1: None arm 2: None | [
1,
0
] | 2 | [
0,
0
] | intervention 1: 3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity intervention 2: 50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity | intervention 1: Interferon-alfa intervention 2: SU011248 | 123 | Jonesboro | Arkansas | United States | -90.70428 | 35.8423
La Jolla | California | United States | -117.2742 | 32.84727
La Jolla | California | United States | -117.2742 | 32.84727
Los Angeles | California | United States | -118.24368 | 34.05223
San Diego | California | United States | -117.16472 | 32.71571
San Francis... | 735 | 0 | 0 | 0 | NCT00083889 | 1COMPLETED | 2008-09-01 | 2004-08-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 341 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to determine the prevalence and clinical course of orthostatic hypotension (OH) on a rehabilitation and nursing home unit during their inpatient stay and to initiate a standardized, interdisciplinary treatment plan for patients with OH and determine the effect of treatment on the clinical c... | This study is a prospective, quasi-experiment conducted in two consecutive phases. During the observation phase, eligible patients are identified and followed through their usual course of care in the nursing home/rehabilitation unit. During the intervention phase, patients enrolled who have OH will receive the interve... | Hypotension, Orthostatic | Aging Blood pressure Hypotension Orthostatic Rehabilitation | null | 1 | arm 1: Stepped intervention consisting of treatment phase 1, 2 and 3. Subjects whose orthostatic hypotension is resolved after treatment phase 1 will not receive new treatments (phase 2 and 3) | [
5
] | 3 | [
10,
0,
10
] | intervention 1: * Patient Education
* Physical Therapy Exercises
* Increased Salt Intake
* Elevation of head of bed with 2-4 inch wedge
* Medication Review by MD, Pharma intervention 2: Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.
* Fludrocortisone
* Salt tablet i... | intervention 1: Treatment Phase 1 intervention 2: Treatment Phase 2 intervention 3: Treatment Phase 3 | 1 | Portland | Oregon | United States | -122.67621 | 45.52345 | 341 | 0 | 0 | 0 | NCT00117585 | 1COMPLETED | 2008-09-01 | 2005-11-01 | VA Office of Research and Development | 1FED | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 515 | NA | SINGLE_GROUP | 2DIAGNOSTIC | 0NONE | true | 0ALL | true | The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease. | null | Heart Failure, Congestive | Heart Failure nuclear cardiology sympathetic innervation 123I-mIBG | null | 1 | arm 1: Single dose | [
0
] | 1 | [
0
] | intervention 1: Single Dose | intervention 1: 123I-mIBG (meta-iodobenzylguanidine) | 1 | Princeton | New Jersey | United States | -74.65905 | 40.34872 | 515 | 0 | 0 | 0 | NCT00126438 | 1COMPLETED | 2008-09-01 | 2005-07-01 | GE Healthcare | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 208 | RANDOMIZED | PARALLEL | 1PREVENTION | 2DOUBLE | false | 0ALL | true | Primary end points
* incidence of depression defined as a Montgomery Asberg Depression Scale Score (MADRS) of 13 or higher during antiviral therapy (up to 48 weeks, depending on genotype)
* effect of an antidepressive pre-treatment over two weeks and a continuously concomitant treatment with Escitalopram (S-citalopram... | null | Depression | Pegasys-Induced depression | null | 2 | arm 1: After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram. arm 2: After the preobservation period, patients received placebo. ... | [
1,
2
] | 4 | [
0,
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly. intervention 4: Patients with HCV genotype 1 or 4 received treatment for 48 ... | intervention 1: Escitalopram intervention 2: Placebo intervention 3: Peginterferon alfa-2a intervention 4: Ribavirin | 1 | Leipzig | N/A | Germany | 12.37129 | 51.33962 | 181 | 0 | 0 | 0 | NCT00136318 | 1COMPLETED | 2008-09-01 | 2004-01-01 | Charite University, Berlin, Germany | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 66 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Bortezomib (Velcade) has just recently been approved by the FDA for the treatment of multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. This study will determine if Velcade is effective in treating patients with multiple myeloma tha... | Primary Objective
• To evaluate the objective response rate (CR + PR) to bortezomib alone in patients with newly diagnosed multiple myeloma.
Secondary Objectives
* To evaluate the tolerability and toxicity.
* To evaluate time to progression.
* To assess the frequency and severity of peripheral neuropathy.
* To evalu... | Multiple Myeloma | multiple myeloma Velcade bortezomib | null | 1 | arm 1: Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment. | [
0
] | 1 | [
0
] | intervention 1: None | intervention 1: bortezomib | 6 | Atlanta | Georgia | United States | -84.38798 | 33.749
Boston | Massachusetts | United States | -71.05977 | 42.35843
Boston | Massachusetts | United States | -71.05977 | 42.35843
Boston | Massachusetts | United States | -71.05977 | 42.35843
Buffalo | New York | United States | -78.87837 | 42.88645
New York | New York |... | 64 | 0 | 0 | 0 | NCT00153920 | 1COMPLETED | 2008-09-01 | 2003-12-01 | Dana-Farber Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 300 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to assess whether a calcineurin inhibitor (CNI)-free regimen with enteric-coated mycophenolate sodium (EC-MPS) and everolimus is as safe and well-tolerated as the standard regimen containing enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine microemulsion, but results in better r... | null | Renal Transplantation | Renal transplantation, everolimus, immunosuppressants, CNI-free | null | 2 | arm 1: Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued t... | [
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL. intervention 2: Tablets orally twice a day to maintain protocol specific target blood levels intervention 3: Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. intervention 4: Corticost... | intervention 1: Everolimus intervention 2: Cyclosporine intervention 3: Enteric-coated mycophenolate sodium intervention 4: Corticosteroids | 3 | Nuremberg | N/A | Germany | 11.07752 | 49.45421
Basel | N/A | Switzerland | 7.57327 | 47.55839
Bern | N/A | Switzerland | 7.44744 | 46.94809 | 300 | 0 | 0 | 0 | NCT00154310 | 1COMPLETED | 2008-09-01 | 2005-06-01 | Novartis | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 89 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy. | null | Carcinoma, Non-Small-Cell Lung | EPO EPO906 Brain metastasis Lung cancer Lung metastasis NSCLC | null | 0 | null | null | 1 | [
0
] | intervention 1: Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendme... | intervention 1: Patupilone | 4 | Louisville | Kentucky | United States | -85.75941 | 38.25424
Columbia | Missouri | United States | -92.33407 | 38.95171
Pittsburgh | Pennsylvania | United States | -79.99589 | 40.44062
Houston | Texas | United States | -95.36327 | 29.76328 | 89 | 0 | 0 | 0 | NCT00171834 | 1COMPLETED | 2008-09-01 | 2003-08-01 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 60 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for relapse of their leukem... | Outline of Therapy:
Combinations of chemotherapy drugs will be given orally, intravenously and intrathecally (directly into the cerebrospinal fluid by spinal tap) over a period of roughly two and a half years.
Therapy will be divided into five phases:
Induction (4 weeks): chemotherapy given to produce a clinical rem... | Acute Lymphocytic Leukemia | Acute Lymphocytic Leukemia Leukemia | null | 2 | arm 1: 6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin arm 2: 6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C | [
0,
0
] | 12 | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] | intervention 1: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation intervention 2: Therapy will be divided into five phases: Induction, Consolidation, De... | intervention 1: aminopterin intervention 2: L-asparaginase intervention 3: cyclophosphamide intervention 4: cytarabine intervention 5: daunomycin intervention 6: dexamethasone intervention 7: 6-mercaptopurine intervention 8: methotrexate intervention 9: 6-thioguanine intervention 10: vincristine intervention 11: Triple... | 2 | Neptune City | New Jersey | United States | -74.02792 | 40.20011
New Brunswick | New Jersey | United States | -74.45182 | 40.48622 | 60 | 0 | 0 | 0 | NCT00176462 | 1COMPLETED | 2008-09-01 | 2001-02-01 | Rutgers, The State University of New Jersey | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 554 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This trial is conducted globally. The purpose of the trial is to evaluate that activated recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity.
Please note that this trial and trial F7TRAUMA-1648 (NCT00323570) have been me... | The decision to discontinue the F7TRAUMA-1711 trial is not due to any safety concerns. The result of the pre-planned futility analysis performed in June 2008 predicted a very low likelihood of reaching a successful outcome on the primary efficacy endpoint at the end of the trial and as a consequence, the company has de... | Acquired Bleeding Disorder Trauma | null | 4 | arm 1: None arm 2: None arm 3: None arm 4: None | [
0,
2,
0,
2
] | 2 | [
0,
0
] | intervention 1: Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.
Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours. intervention 2: placebo | intervention 1: eptacog alfa (activated) intervention 2: placebo | 14 | Princeton | New Jersey | United States | -74.65905 | 40.34872
Säo Paulo | N/A | Brazil | N/A | N/A
Prague | N/A | Czechia | 14.42076 | 50.08804
Paris La Défense Cedex | N/A | France | N/A | N/A
Mainz | N/A | Germany | 8.2791 | 49.98419
Vouliagment | N/A | Greece | N/A | N/A
Kowloon | N/A | Hong Kong | 114.18333 | 22.31... | 560 | 0 | 0 | 0 | NCT00184548 | 6TERMINATED | 2008-09-01 | 2005-10-01 | Novo Nordisk A/S | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 47 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | true | 0ALL | false | Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is the good cholesterol helping to protect against heart disease. Currently one known treatme... | It has been estimated that approximately ¼ of the US population has the Insulin Resistant Syndrome (IRS). The notion that insulin resistance and compensatory hyperinsulinemia lead to a cluster of abnormalities that increase CVD risk was first introduced in 1988, and central to the changes identified was a dyslipidemia ... | Insulin Resistance Hypertriglyceridemia | Insulin resistance Insulin resistance syndrome dyslipidemia atherogenic dyslipidemia triglyceride/HDL-C ratio | null | 3 | arm 1: 160 mg daily for 12 weeks arm 2: 4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks arm 3: calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks | [
1,
1,
1
] | 3 | [
0,
0,
5
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: Rosiglitazone intervention 2: Fenofibrate intervention 3: Weight Loss | 1 | Stanford | California | United States | -122.16608 | 37.42411 | 47 | 0 | 0 | 0 | NCT00186537 | 1COMPLETED | 2008-09-01 | 2003-09-01 | Stanford University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 107 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics. | Implantable insulin delivery pumps have been shown to reduce the occurrence of severe hypoglycemia in Type 1 DM subjects, as demonstrated in numerous European studies. Glycemic control is difficult to attain in subjects using exogenous insulin due to the risk of severe hypoglycemia. This study is aimed at comparing the... | Type 1 Diabetes | Diabetes Implantable Insulin Pump Intraperitoneal Insulin Delivery | null | 2 | arm 1: The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill... | [
0,
4
] | 3 | [
0,
1,
0
] | intervention 1: 400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements. intervention 2: The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes. intervention 3: 400 IU per ml - dosage based on the I... | intervention 1: Medtronic MiniMed Implantable Pump Human Recombinant Insulin intervention 2: Medtronic MiniMed Implantable Pump System intervention 3: Aventis HOE21PH U400 | 5 | Santa Barbara | California | United States | -119.69819 | 34.42083
Aurora | Colorado | United States | -104.83192 | 39.72943
North Kansas City | Missouri | United States | -94.56218 | 39.13
Wooser | Ohio | United States | N/A | N/A
San Antonio | Texas | United States | -98.49363 | 29.42412 | 107 | 0 | 0 | 0 | NCT00211536 | 1COMPLETED | 2008-09-01 | 2002-06-01 | Medtronic Diabetes | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 20 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | true | 0ALL | true | Although nasal polyposis has been recognized as an inflammatory process for many years, the true etiology of nasal polyposis mainly unknown. Despite surgical removal, the recurrence rate after surgery has been reported as high as 87% within the first year after surgery. Anecdotally the Principal Investigator found an i... | Although nasal polyposis has been recognized as an inflammatory process for many years, the true etiology of nasal polyposis mainly unknown. Despite surgical removal, the recurrence rate after surgery has been reported as high as 87% within the first year after surgery. Anecdotally the Principal Investigator found an i... | Nasal Polyps Gastroesophageal Reflux | Nasal polyps Gastroesophageal Reflux | null | 0 | null | null | 1 | [
0
] | intervention 1: Lansoprazole 30 mg BID for 1 year | intervention 1: lansoprazole | 1 | Indianapolis | Indiana | United States | -86.15804 | 39.76838 | 0 | 0 | 0 | 0 | NCT00215787 | 1COMPLETED | 2008-09-01 | 2005-09-01 | Head and Neck Surgery Associates | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 57 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder. | This study will use a multicenter, randomized, open-label, active-controlled, dose-titration, parallel group design, in approximately pediatric patients with detrusor overactivity associated with a neurological condition. | Detrusor Hyperreflexia | null | 2 | arm 1: Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day arm 2: 5 to 15 mg/day immediate release or extended release tablets, or syrup | [
0,
1
] | 2 | [
0,
0
] | intervention 1: 1.3, 2.6, 3.9 mg/day transdermal intervention 2: 5 to 15 mg/day immediate release or extended release tablets, or syrup | intervention 1: Oxybutynin intervention 2: Oxybutynin | 23 | Little Rock | Arkansas | United States | -92.28959 | 34.74648
Orange County | California | United States | N/A | N/A
San Diego | California | United States | -117.16472 | 32.71571
Denver | Colorado | United States | -104.9847 | 39.73915
Washington D.C. | District of Columbia | United States | -77.03637 | 38.89511
Detro... | 55 | 0 | 0 | 0 | NCT00224016 | 1COMPLETED | 2008-09-01 | 2004-12-01 | Watson Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 473 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolutio... | null | Appendicitis Cholecystitis Diverticulitis Intra-Abdominal Abscess Intra-Abdominal Infection Peritonitis | Intra-Abdominal Infections Abscess | null | 2 | arm 1: None arm 2: None | [
1,
1
] | 2 | [
0,
0
] | intervention 1: every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours) intervention 2: Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the di... | intervention 1: tigecycline intervention 2: ceftriaxone plus metronidazole | 68 | Nambour | Queensland | Australia | 152.95941 | -26.62613
Cairns | N/A | Australia | 145.76613 | -16.92366
Parkville | N/A | Australia | 144.95 | -37.78333
Shanghai | N/A | China | 121.45806 | 31.22222
Odense | N/A | Denmark | 10.38831 | 55.39594
Lahti | N/A | Finland | 25.66151 | 60.98267
Seinäjoki | N/A | Finland | 22... | 467 | 0 | 0 | 0 | NCT00230971 | 1COMPLETED | 2008-09-01 | 2005-10-01 | Wyeth is now a wholly owned subsidiary of Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 52 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | Randomized clinical trial of sertraline vs. placebo for post-TBI depression | Purpose: The purpose of this study is to document the efficacy of sertraline (Zoloft) in the treatment of depression (major depressive disorder) after TBI, including the impact on quality of life. Researchers will also explore the effects of sertraline on anxiety disorders, which often accompany post-TBI depression.
B... | Depression | Sertraline TBI depression SSRI brain injury | null | 2 | arm 1: Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg). arm 2: Placebo for 10 weeks. | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Sertraline arm intervention 2: Placebo | intervention 1: Sertraline intervention 2: Placebo | 1 | New York | New York | United States | -74.00597 | 40.71427 | 41 | 0 | 0 | 0 | NCT00233103 | 1COMPLETED | 2008-09-01 | 2003-06-01 | Icahn School of Medicine at Mount Sinai | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 52 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This research project is an open-label, randomized study for the use of Nitric Oxide in pediatric patients with acute respiratory distress syndrome (ARDS). The study examines whether nitric oxide (NO) treatment impacts the the P:F ratio (arterial partial pressure of oxygen (PaO2) divided by fraction of inspired oxygen ... | At low concentrations, nitric oxide(NO) functions as a cellular messenger and regulator of microcirculation. NO may have an important role in the pathogenesis of ARDS as well as its treatment. NO may be primarily useful in improving matching of ventilation and perfusion in the lung. The aims of the study are to attempt... | Acute Respiratory Distress Syndrome | Acute Respiratory Distress Syndrome ARDS Nitric Oxide | null | 2 | arm 1: Subjects will be randomized to receive Nitric Oxide (NO) immediately after study entry, given at 10 parts per million (ppm) for the first 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide (NO) will be turned of... | [
1,
1
] | 2 | [
0,
10
] | intervention 1: Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour. intervention 2: Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once ... | intervention 1: Nitric Oxide intervention 2: No Intervention | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 52 | 0 | 0 | 0 | NCT00240487 | 1COMPLETED | 2008-09-01 | 2000-09-01 | Children's Hospital of Philadelphia | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 39 | RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 2DOUBLE | true | 2MALE | true | This study will look at the effects of a soy supplement called Revival on memory, quality of life, and hot flashes in men with prostate cancer who are being treated with testosterone suppression therapy. Hypothesis: Treating men who have prostate CA with daily Revival will result in at least a 50% reduction in hot flas... | This research study will look at the effects of a soy supplement called Revival on memory, quality of life, and hot flashes in men with prostate cancer who are undergoing (ADT) androgen deprivation therapy. Participants will be given either placebo or Revival. Participants will be asked to take their supplement once/da... | Hot Flashes | prostate cancer soy androgen deprivation quality of life isoflavones | null | 2 | arm 1: Isoflavone arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: Isoflavone intervention 2: Placebos | 1 | Baltimore | Maryland | United States | -76.61219 | 39.29038 | 33 | 0 | 0 | 0 | NCT00245518 | 1COMPLETED | 2008-09-01 | 2005-06-01 | Johns Hopkins University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 93 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children. | Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders in children. Children with ADHD often have impaired functioning in home and school and usually experience difficulty relating to peers. If left untreated, the disorder can have long-term adverse effects into adolescence and adult... | Attention Deficit Disorder With Hyperactivity | ADHD Atomoxetine | null | 2 | arm 1: atomoxetine capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks arm 2: matching placebo capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks | [
0,
2
] | 3 | [
0,
0,
5
] | intervention 1: Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation. intervention 2: Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation. intervention 3: All children will receive parent training for the duration of... | intervention 1: Atomoxetine intervention 2: Placebo intervention 3: Parent Training | 3 | Omaha | Nebraska | United States | -95.94043 | 41.25626
New York | New York | United States | -74.00597 | 40.71427
Durham | North Carolina | United States | -78.89862 | 35.99403 | 93 | 0 | 0 | 0 | NCT00254462 | 1COMPLETED | 2008-09-01 | 2005-10-01 | University of Nebraska | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 7 | RANDOMIZED | PARALLEL | 4SUPPORTIVE_CARE | 0NONE | false | 0ALL | true | RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia.
PURPOSE: This randomized clinical trial is studying how well epoetin alfa works in treating patients with anemia who are under... | OBJECTIVES:
Primary
* Determine the efficacy, in terms of maintenance of target hemoglobin and hematocrit levels, of interval dosing with epoetin alfa in treating patients with anemia undergoing chemotherapy for nonhematologic cancer.
Secondary
* Determine the pharmacokinetics and pharmacodynamics of this drug in t... | Anemia Fatigue Unspecified Adult Solid Tumor, Protocol Specific | fatigue anemia unspecified adult solid tumor, protocol specific | null | 3 | arm 1: Weekly dosing schedule subjects will get the study drug once every week until the end of the study. arm 2: Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. ... | [
1,
0,
0
] | 2 | [
0,
0
] | intervention 1: The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other ... | intervention 1: Weekly procrit dosing intervention 2: Interval Dosing | 1 | Portland | Oregon | United States | -122.67621 | 45.52345 | 7 | 0 | 0 | 0 | NCT00258440 | 6TERMINATED | 2008-09-01 | 2003-05-01 | OHSU Knight Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 406 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma.
THIS STUDY I... | null | Asthma | Asthma omalizumab Severe persistent allergic asthma | null | 2 | arm 1: During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection... | [
0,
1
] | 2 | [
0,
10
] | intervention 1: Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level. intervention 2: Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study. | intervention 1: Omalizumab intervention 2: Optimized asthma therapy | 17 | Brussels | N/A | Belgium | 4.34878 | 50.85045
Montreal | N/A | Canada | -73.58781 | 45.50884
Hvidovre | N/A | Denmark | 12.47708 | 55.64297
Berlin | N/A | Germany | 13.41053 | 52.52437
Athens | N/A | Greece | 23.72784 | 37.98376
Budapest | N/A | Hungary | 19.04045 | 47.49835
Dublin | N/A | Ireland | -6.24889 | 53.33306... | 402 | 0 | 0 | 0 | NCT00264849 | 1COMPLETED | 2008-09-01 | 2005-11-01 | Novartis | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 1,565 | RANDOMIZED | PARALLEL | 1PREVENTION | 3TRIPLE | true | 1FEMALE | true | This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. In addition, there is an opportunity for subjects to continue with study... | Approximately 85% of American women (52 million) between the ages of 15 and 44 are sexually active . Approximately two-thirds or 38 million women use some form of birth control and/or STD prevention. With growing awareness of the risk of STDs, increasing numbers of women will require contraceptive methods that provide ... | Pregnancy | contraception | null | 2 | arm 1: C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel arm 2: Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel. | [
0,
1
] | 2 | [
0,
0
] | intervention 1: The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study. intervention 2: The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the ... | intervention 1: C31G intervention 2: nonoxynol-9 (N-9) | 15 | Berkeley | California | United States | -122.27275 | 37.87159
Los Angeles | California | United States | -118.24368 | 34.05223
Aurora | Colorado | United States | -104.83192 | 39.72943
Baltimore | Maryland | United States | -76.61219 | 39.29038
Springfield | Massachusetts | United States | -72.58981 | 42.10148
New York... | 1,396 | 0 | 0 | 0 | NCT00274261 | 1COMPLETED | 2008-09-01 | 2004-06-01 | Health Decisions | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 40 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | true | 0ALL | false | The purpose of this research study is to investigate different doses of proton pump inhibitors in reducing cough symptoms felt to be associated with Gastroesophageal reflux disease (GERD). Proton pump inhibitors are medicines used to treat GERD, which work by lowering the amount of acid in the stomach.
The proton pump... | This study will be a randomized, double-blind, placebo controlled, comparative parallel-group trial of subjects with chronic cough of unknown origin presenting to the Otolaryngology/ Head and Neck Surgery, Pulmonary Medicine, and Gastroenterology outpatient clinics at the University of North Carolina Hospital system.
... | Cough GERD | Cough GERD | null | 2 | arm 1: 40mg Esomeprazole BID arm 2: placebo capsules | [
0,
2
] | 2 | [
0,
0
] | intervention 1: 40mg capsule BID for 12 weeks intervention 2: placebo capsule BID for 12 weeks | intervention 1: Esomeprazole intervention 2: Placebo | 1 | Chapel Hill | North Carolina | United States | -79.05584 | 35.9132 | 40 | 0 | 0 | 0 | NCT00287339 | 1COMPLETED | 2008-09-01 | 2005-09-01 | University of North Carolina, Chapel Hill | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 1,523 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will pro... | null | Chronic Obstructive Pulmonary Disease (COPD) | Roflumilast COPD Chronic obstructive pulmonary disease | null | 2 | arm 1: 500 mcg, once daily, oral administration in the morning arm 2: once daily | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 500 mcg, once daily, oral administration in the morning intervention 2: once daily | intervention 1: Roflumilast intervention 2: Placebo | 179 | Fullerton | California | United States | -117.92534 | 33.87029
Los Angeles | California | United States | -118.24368 | 34.05223
Los Angeles | California | United States | -118.24368 | 34.05223
Palmdale | California | United States | -118.11646 | 34.57943
Rancho Mirage | California | United States | -116.41279 | 33.7397... | 1,524 | 0 | 0 | 0 | NCT00297102 | 1COMPLETED | 2008-09-01 | 2006-02-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 37 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The aim of this study is to compare the responsiveness of lower airways in adult patients with stable asthma after treatment with ciclesonide and fluticasone propionate. Treatment medication will be administered as follows: ciclesonide will be inhaled once daily at one dose level, fluticasone propionate will be inhaled... | null | Asthma | Asthma AMP Ciclesonide Fluticasone propionate | null | 2 | arm 1: Ciclesonide 160 µg arm 2: Fluticasone 100 µg | [
1,
1
] | 2 | [
0,
0
] | intervention 1: inhaled Ciclesonide 160 µg, once daily in the morning intervention 2: inhaled Fluticasone 100 µg, twice daily | intervention 1: Ciclesonide intervention 2: Fluticasone | 1 | RB Groningen | N/A | Netherlands | N/A | N/A | 37 | 0 | 0 | 0 | NCT00306163 | 1COMPLETED | 2008-09-01 | 2006-05-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 60 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | false | 0ALL | null | The purpose of this study is to determine whether food has any effect on a single dose of Cediranib (AZD2171, Recentin™)followed by an assessment of the safety and tolerability of fixed daily dosing in comparison to varying dose levels on a patient-by-patient basis. | null | Cancer | Advanced solid tumours Advanced cancer tumor tumour RECENTIN | null | 4 | arm 1: Part A: Cediranib 45 mg Fed State arm 2: Part A: Cediranib 45 mg Fasted State arm 3: Part B: Cediranib 45 mg Fixed Dose arm 4: Part B: Cediranib 30 - 90 mg Dose Escalation | [
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: 45 mg oral dose intervention 2: oral tablet dose escalation | intervention 1: Cediranib intervention 2: Cediranib 30 - 90 mg | 4 | Glasgow | N/A | United Kingdom | -4.25763 | 55.86515
Headington | N/A | United Kingdom | -1.21974 | 51.75737
London | N/A | United Kingdom | -0.12574 | 51.50853
Manchester | N/A | United Kingdom | -2.23743 | 53.48095 | 86 | 0 | 0 | 0 | NCT00306891 | 1COMPLETED | 2008-09-01 | 2006-06-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 677 | RANDOMIZED | PARALLEL | 1PREVENTION | 0NONE | false | 0ALL | null | The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes. | null | Diabetes Type 2 | null | 2 | arm 1: Technosphere® Insulin Inhalation Powder + insulin glargine arm 2: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Inhalation, 15U/30U intervention 2: BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc | intervention 1: Technosphere® Insulin Inhalation Powder intervention 2: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) | 151 | Mobile | Alabama | United States | -88.04305 | 30.69436
Tucson | Arizona | United States | -110.92648 | 32.22174
Tucson | Arizona | United States | -110.92648 | 32.22174
Tucson | Arizona | United States | -110.92648 | 32.22174
Chula Vista | California | United States | -117.0842 | 32.64005
Fresno | California | United ... | 654 | 0 | 0 | 0 | NCT00309244 | 1COMPLETED | 2008-09-01 | 2006-02-01 | Mannkind Corporation | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
3
] | 11 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Sarcoidosis is a rare disease that can affect any organ in the body. It is characterized by the buildup of immune-system (fights off infection in the body) cells in organs. These cells form small groups called granulomas, which lead to inflammation of the surrounding tissue. Sarcoidosis most commonly affects the lung a... | This study consists of 11 visits (including screening).
Screening Procedures:
A chest radiograph (PA and lateral) must be obtained within 3 months prior to the first study injection. It must indicate that subject is free of tuberculosis (TB). The chest radiograph will also be used to confirm the stage of the disease.... | Sarcoidosis | Sarcoidosis Humira Adalimumab Tumor Necrosis Factor Inhibitors | null | 1 | arm 1: Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52 | [
0
] | 1 | [
0
] | intervention 1: Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks. | intervention 1: Adalimumab | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 11 | 0 | 0 | 0 | NCT00311246 | 6TERMINATED | 2008-09-01 | 2006-04-01 | University of Chicago | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 768 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes | All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requ... | Diabetes | null | 3 | arm 1: Metformin 500-2500 mg (as needed) arm 2: Metformin 500-2500 mg (as needed) arm 3: Metformin 500-2500 mg (as needed) | [
0,
0,
2
] | 6 | [
0,
0,
0,
0,
0,
0
] | intervention 1: Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\]) intervention 2: Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT). intervention 3: Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT) intervention 4: Tablets, Oral, 0 mg, Daily AM/PM, (24 wee... | intervention 1: Saxagliptin intervention 2: Saxagliptin intervention 3: Glyburide intervention 4: Placebo intervention 5: Glyburide intervention 6: Metformin | 115 | Jonesboro | Arkansas | United States | -90.70428 | 35.8423
Searcy | Arkansas | United States | -91.73625 | 35.25064
Alhambra | California | United States | -118.12701 | 34.09529
Fountain Valley | California | United States | -117.95367 | 33.70918
Fresno | California | United States | -119.77237 | 36.74773
Los Angeles |... | 768 | 0 | 0 | 0 | NCT00313313 | 1COMPLETED | 2008-09-01 | 2006-04-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 220 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP) | null | Central Neuropathic Pain | Post-stroke pain, pregabalin | null | 2 | arm 1: The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo. arm 2: The change in pain scores from baseline to endpoint will be compared among the two treatm... | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clin... | intervention 1: Pregabalin intervention 2: Placebo | 33 | Darlinghurst | New South Wales | Australia | 151.21925 | -33.87939
East Gosford | New South Wales | Australia | 151.35338 | -33.43874
St Leonards | New South Wales | Australia | 151.19836 | -33.82344
Warrawong | New South Wales | Australia | 150.88833 | -34.485
Herston | Queensland | Australia | 153.01852 | -27.44453
F... | 219 | 0 | 0 | 0 | NCT00313820 | 1COMPLETED | 2008-09-01 | 2006-08-01 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 225 | RANDOMIZED | PARALLEL | 1PREVENTION | 3TRIPLE | false | 0ALL | true | RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of budesonide may keep lung cancer from forming in patients with lung nodules.
PURPOSE: This randomized phase II trial is studying how well inhalation budesonide works in treating patients with lung nod... | OBJECTIVES:
Primary
* Evaluate the effect, in terms of size and number reduction of computed tomography (CT) scan-detected undetermined lung nodules, in asymptomatic subjects with lung nodules at high-risk for developing lung cancer treated with inhaled budesonide vs placebo.
Secondary
* Compare average modificatio... | Lung Cancer | Small cell lung cancer Non-small cell lung cancer Budesonide Entocort EC Pulmicort Respules Rhinocort aqua Aerosol budesonide treatment Smoking | null | 2 | arm 1: Inhaled Budesonide 800 ug twice daily for 1 year arm 2: Inhaled placebo twice daily for 1 year | [
0,
2
] | 2 | [
0,
10
] | intervention 1: Inhaled Budesonide 800 micrograms (ug) twice daily for one year. intervention 2: Inhaled placebo twice daily for one year. | intervention 1: Budesonide intervention 2: Placebo | 1 | Milan | N/A | Italy | 9.18951 | 45.46427 | 199 | 0 | 0 | 0 | NCT00321893 | 1COMPLETED | 2008-09-01 | 2006-01-01 | National Cancer Institute (NCI) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 92 | NON_RANDOMIZED | SINGLE_GROUP | 2DIAGNOSTIC | 0NONE | false | 0ALL | false | The purpose of this study was to assess the safety and enhancing properties of the magnetic resonance imaging (MRI) contrast agent MultiHance in children aged 2 to 17 years having central nervous system (CNS) disorders. | null | Central Nervous System Diseases | disease of the central nervous system (brain or spine) | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose. | intervention 1: gadobenate dimeglumine | 1 | Princeton | New Jersey | United States | -74.65905 | 40.34872 | 92 | 0 | 0 | 0 | NCT00323310 | 6TERMINATED | 2008-09-01 | 2006-04-01 | Bracco Diagnostics, Inc | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 404 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This is an initial placebo-controlled study followed by open treatment evaluating the effectiveness and tolerability of ropinirole long-term in patients with moderate to severe Restless Legs Syndrome. | A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs S... | Restless Legs Syndrome | Moderate Restless Legs Syndrome Severe ropinirole | null | 2 | arm 1: Double-blind (Ropinirole:Placebo) for 12 to 26 weeks arm 2: Open label ropinirole for 40 weeks | [
2,
5
] | 2 | [
0,
0
] | intervention 1: Matching Placebo intervention 2: Ropinirole IR 0.25mg/day to 4mg/day for RLS | intervention 1: Placebo intervention 2: Ropinirole | 39 | Camperdown | New South Wales | Australia | 151.17642 | -33.88965
Kippa-Ring | Queensland | Australia | 153.0835 | -27.22586
Woodville | South Australia | Australia | 138.54291 | -34.877
Clayton | Victoria | Australia | 145.11667 | -37.91667
East Melbourne | Victoria | Australia | 144.9879 | -37.81667
Olomouc | N/A | Cz... | 673 | 0 | 0 | 0 | NCT00329602 | 1COMPLETED | 2008-09-01 | 2006-03-01 | GlaxoSmithKline | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 206 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip once a day in patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. And in addition, this study ... | null | Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic lateral sclerosis free radical scavenger | null | 2 | arm 1: MCI-186 arm 2: Placebo of MCI-186 | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles). intervention 2... | intervention 1: MCI-186 intervention 2: Placebo of MCI-186 | 0 | null | 206 | 0 | 0 | 0 | NCT00330681 | 1COMPLETED | 2008-09-01 | 2006-05-01 | Mitsubishi Tanabe Pharma Corporation | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 95 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab. | null | Metastatic Colorectal Cancer Skin Rash Skin Toxicities Colon Cancer Colorectal Cancer | STEPP STEP STEEP mCRC Skin Toxicities Skin Rash Metastatic Colorectal Cancer Anti-EGFr Skin Rash colon cancer colorectal cancer rectal cancer | null | 2 | arm 1: Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to c... | [
0,
0
] | 5 | [
2,
0,
0,
0,
0
] | intervention 1: Administered by intravenous infusion intervention 2: Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines. intervention 3: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Rec... | intervention 1: Panitumumab intervention 2: Irinotecan intervention 3: FOLFIRI intervention 4: Pre-emptive Skin Treatment intervention 5: Reactive Skin Treatment | 0 | null | 95 | 0 | 0 | 0 | NCT00332163 | 1COMPLETED | 2008-09-01 | 2006-04-01 | Amgen | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 25 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania. | The proposed study will consist of 8 weeks of treatment with either naltrexone or placebo in 20 subjects with kleptomania. The hypothesis to be tested is that naltrexone will be effective in reducing the urges to steal in patients with kleptomania. The proposed study will provide needed data on the treatment of a disab... | Kleptomania | Compulsive Shoplifting Kleptomania Compulsive Stealing | null | 2 | arm 1: Naltrexone arm 2: Placebo | [
1,
2
] | 2 | [
0,
0
] | intervention 1: daily intervention 2: daily | intervention 1: Naltrexone intervention 2: Placebo | 1 | Minneapolis | Minnesota | United States | -93.26384 | 44.97997 | 25 | 0 | 0 | 0 | NCT00332579 | 1COMPLETED | 2008-09-01 | 2006-05-01 | University of Minnesota | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 64 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis | null | Peritoneal Neoplasms Intestinal Obstruction Carcinomatosis | bowel obstruction, peritoneal carcinomatosis Octreotide inoperable | null | 2 | arm 1: Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection o... | [
0,
2
] | 4 | [
0,
0,
0,
0
] | intervention 1: Octreotide long-acting release (LAR) 30 mg intramuscular injection. intervention 2: Immediate-release Octreotide supplied in 100 µg/mL ampules. intervention 3: methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections). intervention 4: Physiologic saline solution | intervention 1: Octreotide LAR intervention 2: Octreotide (Immediate release) intervention 3: methylprednisolone intervention 4: Placebo | 1 | Créteil | N/A | France | 2.46569 | 48.79266 | 64 | 0 | 0 | 0 | NCT00332696 | 1COMPLETED | 2008-09-01 | 2005-09-01 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 16 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan. | null | Tumors | Solid tumors (including relapsed disease) that are refractory to standard therapies or for which no effective standard therapy exists | null | 3 | arm 1: None arm 2: None arm 3: None | [
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: tablets, Oral, 100 mg, once daily for 4 weeks intervention 2: tablets, Oral, 150 mg, once daily, 4 weeks intervention 3: tablets, Oral, 200 mg, once daily for 4 weeks | intervention 1: Dasatinib intervention 2: Dasatinib intervention 3: Dasatinib | 2 | Sayama | Osaka | Japan | 135.56298 | 34.51685
Koto-Ku | Tokyo | Japan | N/A | N/A | 16 | 0 | 0 | 0 | NCT00339144 | 1COMPLETED | 2008-09-01 | 2007-01-01 | Bristol-Myers Squibb | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 388 | null | PARALLEL | 0TREATMENT | null | false | 0ALL | null | This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of tiotropium compared to salmeterol in moderate persistent asthmatic (GINA step 3) patients homozygous for arginine at the 16th amino acid positio... | null | Asthma | null | 0 | null | null | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: Tiotropium bromide intervention 2: Placebo intervention 3: Salmeterol xinafoate | 109 | Graz | N/A | Austria | 15.45 | 47.06667
Trofaiach | N/A | Austria | 15.00681 | 47.42524
Vienna | N/A | Austria | 16.37208 | 48.20849
Vienna | N/A | Austria | 16.37208 | 48.20849
Vienna | N/A | Austria | 16.37208 | 48.20849
Vienna | N/A | Austria | 16.37208 | 48.20849
Wels | N/A | Austria | 14.03333 | 48.16667
Anderlech... | 388 | 0 | 0 | 0 | NCT00350207 | 1COMPLETED | 2008-09-01 | 2006-07-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2,
3
] | 8 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | This is a Phase I/II trial of elderly patients (\> 70 years of age). Patients in this age group with previously un-treated Advanced Stage Non-Squamous Non-Small Cell Lung Cancer (NSCLC) with Stage IIIB (with malignant pleural effusion) and stage IV disease will be enrolled. Therapy consists of three drugs (Premetrexed\... | This is a Phase I/II trial of elderly patients (\> 70 years of age) with previously un-treated Advanced Stage Non-Squamous NSCLC with Stage IIIB (with malignant pleural effusion) and stage IV disease will be enrolled.
Treatment Regimen:
Premetrexed (Alimta™) 500 milligrams(mg)/Meter squared(m20 Intravenous(I.V.) Day ... | Non-Small Cell Lung Cancer | null | 1 | arm 1: Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer | [
0
] | 3 | [
0,
0,
0
] | intervention 1: Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days. intervention 2: Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days. intervention 3: Treatment Regimen Item 3: Preme... | intervention 1: Bevacizumab intervention 2: Erlotinib intervention 3: Pemetrexed | 1 | Tampa | Florida | United States | -82.45843 | 27.94752 | 8 | 0 | 0 | 0 | NCT00351039 | 6TERMINATED | 2008-09-01 | 2006-07-01 | H. Lee Moffitt Cancer Center and Research Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 42 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | Reactive arthritis, also known as Reiter's syndrome, is a form of arthritis that occurs as a reaction to an infection elsewhere in the body. It is characterized by inflammation of the joints, tendons, urogenital tract, and eyes. Pain and swelling in the knees, ankles, and feet are common. This study will determine the ... | The initial infection that causes reactive arthritis is caused by one of two bacteria: Chlamydia trachomatis, which is usually acquired through sexual contact, or Chlamydia pneumoniae, which can cause respiratory infections. Most people recover fully from the initial flare of arthritis symptoms. However, about 20% of p... | Arthritis, Reactive Reiter Disease | Chlamydia | null | 3 | arm 1: Participants received Azithromycin and Rifampin arm 2: Participants received Doxycycline and Rifampin arm 3: Participants received placebo | [
1,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: doxycycline 100mg daily; rifampin 300mg daily (both for 6 months) intervention 2: Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months) intervention 3: Methylcellulose | intervention 1: Doxycycline and Rifampin intervention 2: Azithromycin and Rifampin intervention 3: Placebo | 3 | Tampa | Florida | United States | -82.45843 | 27.94752
New Orleans | Louisiana | United States | -90.07507 | 29.95465
Toronto | Ontario | Canada | -79.39864 | 43.70643 | 42 | 0 | 0 | 0 | NCT00351273 | 1COMPLETED | 2008-09-01 | 2006-05-01 | University of South Florida | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 50 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania | The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective and well tolerated in patients with trichotill... | Trichotillomania | Trichotillomania Hair-pulling | null | 2 | arm 1: N-Acetyl Cysteine arm 2: Placebo | [
1,
2
] | 2 | [
0,
0
] | intervention 1: daily intervention 2: 600mg capsules in varying doses for 12 weeks. | intervention 1: Placebo intervention 2: N-Acetyl Cysteine | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 50 | 0 | 0 | 0 | NCT00354770 | 1COMPLETED | 2008-09-01 | 2006-07-01 | University of Chicago | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 10 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S. Food and Drug Administration) approved for use in people who have schizophrenia and psychotic symptoms. Fluphenazine decan... | Psoriasis is a hyperproliferative, inflammatory, immune-mediated skin disease that affects approximately 2% of the United States and European populations (Tutrone 2001, Kipnis 2005). This disease manifests as red, scaly plaques that are itchy and/or painful. Patients with psoriasis may be socially stigmatized because o... | Psoriasis | null | 2 | arm 1: Treated with fluphenazine arm 2: Treated with Placebo | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: "APP Pharmaceuticals" is the name of the pharm... | intervention 1: Fluphenazine Decanoate intervention 2: Placebo | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 10 | 0 | 0 | 0 | NCT00356200 | 6TERMINATED | 2008-09-01 | 2006-07-01 | Tufts Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 12 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days every 3 weeks (this is considered as 1 cycle) to su... | Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered intravenously over 1 hour daily for 5 days every 3 weeks (this is considered as 1 cycle) to su... | Solid Tumors Lymphoma | Tumor Lymphoma Zalypsis PharmaMar PM00104 | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Intravenously over 1 hour daily for 5 days, every 3 weeks. | intervention 1: PM00104 | 2 | Boston | Massachusetts | United States | -71.05977 | 42.35843
Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 11 | 0 | 0 | 0 | NCT00359294 | 6TERMINATED | 2008-09-01 | 2006-05-01 | PharmaMar | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 171 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease. | null | Alzheimer's Disease | Alzheimer Dementia | null | 3 | arm 1: AC-3933, 5mg twice daily arm 2: AC-3933, 20 mg twice daily arm 3: Sugar Pill twice daily | [
0,
0,
2
] | 3 | [
0,
0,
10
] | intervention 1: 5mg twice daily intervention 2: AC-3933, 20 mg twice daily intervention 3: Sugar Pill twice daily | intervention 1: AC-3933 intervention 2: AC-3933 intervention 3: Sugar Pill | 34 | LIttle Rock | Alaska | United States | N/A | N/A
Phoenix | Arizona | United States | -112.07404 | 33.44838
Little Rock | Arkansas | United States | -92.28959 | 34.74648
Bakersfield | California | United States | -119.01871 | 35.37329
Berkeley | California | United States | -122.27275 | 37.87159
Fresno | California | Un... | 154 | 0 | 0 | 0 | NCT00359944 | 1COMPLETED | 2008-09-01 | 2006-02-01 | Sumitomo Pharma America, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
[
5
] | 17 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | true | 0ALL | false | People with allergies frequently complain of a loss or reduction in the sense of smell.
In this study, the investigators propose to perform a randomized, double blind, placebo controlled parallel study of subjects with nasal allergies and decreased smell to determine the effect of a treatment for allergies on the sens... | null | Seasonal Allergic Rhinitis | null | 2 | arm 1: Mometasone intranasal steroid therapy daily for 2 weeks arm 2: 2 puffs of placebo spray in each nostril once daily | [
1,
2
] | 2 | [
0,
0
] | intervention 1: 2 puffs in each nostril once daily of nasal spray intervention 2: 2 puffs in each nostril once daily of nasal spray | intervention 1: Mometasone intervention 2: Placebo | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 17 | 0 | 0 | 0 | NCT00361439 | 6TERMINATED | 2008-09-01 | 2006-08-01 | University of Chicago | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 39 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to determine if the study drug is effective and safe in the treatment of Multiple Sclerosis (MS) in patients of Chinese origin. | The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany.
Bayer HealthCare AG, Germany is the sponsor of the trial. | Multiple Sclerosis | MS | null | 1 | arm 1: Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.) | [
0
] | 1 | [
0
] | intervention 1: Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.) | intervention 1: Interferon beta-1b (Betaseron, BAY86-5046) | 3 | Beijing | N/A | China | 116.39723 | 39.9075
Beijing | N/A | China | 116.39723 | 39.9075
Shanghai | N/A | China | 121.45806 | 31.22222 | 39 | 0 | 0 | 0 | NCT00370071 | 1COMPLETED | 2008-09-01 | 2006-11-01 | Bayer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 19 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles. Pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action. Purpose of the trial is to monitor the blood values of these biomolecules at different... | null | Non Small Cell Lung Cancer | null | 2 | arm 1: None arm 2: None | [
0,
0
] | 2 | [
0,
0
] | intervention 1: 500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue intervention 2: 500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable to... | intervention 1: Pemetrexed - Before Protocol Amendment intervention 2: Pemetrexed - After Protocol Amendment | 1 | Milan | N/A | Italy | 12.59836 | 42.78235 | 19 | 0 | 0 | 0 | NCT00370292 | 1COMPLETED | 2008-09-01 | 2006-09-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 55 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | false | This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer. | null | Breast Cancer Metastasis | Recurrent, locally-advanced, or 'triple negative' metastatic breast cancer | null | 2 | arm 1: None arm 2: None | [
0,
0
] | 2 | [
0,
0
] | intervention 1: Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months) intervention 2: Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months) | intervention 1: Dasatinib intervention 2: Dasatinib | 10 | San Francisco | California | United States | -122.41942 | 37.77493
Jacksonville | Florida | United States | -81.65565 | 30.33218
Boston | Massachusetts | United States | -71.05977 | 42.35843
The Bronx | New York | United States | -73.86641 | 40.84985
Houston | Texas | United States | -95.36327 | 29.76328
Paris | N/A | ... | 44 | 0 | 0 | 0 | NCT00371254 | 1COMPLETED | 2008-09-01 | 2006-12-01 | Bristol-Myers Squibb | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 26 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | true | 0ALL | null | The purpose of this study is to investigate whether aripiprazole will decrease cocaine self-administration, subjective effects and cravings compared to placebo. | Despite the recent increase in data about cocaine's basic neurochemical mechanisms of action, progress towards the development of an effective pharmacological treatment for cocaine abuse has been disappointing. We are proposing to use our laboratory model of repeated dose cocaine self-administration to assess the poten... | Cocaine Abuse | Aripiprazole Cocaine abuse | null | 2 | arm 1: Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg). arm 2: Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg) | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg). intervention 2: Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg). | intervention 1: Aripiprazole + Cocaine intervention 2: Placebo + Cocaine | 1 | New York | New York | United States | -74.00597 | 40.71427 | 16 | 0 | 0 | 0 | NCT00373880 | 1COMPLETED | 2008-09-01 | 2005-04-01 | New York State Psychiatric Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 99 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | Palifermin is a modified version of a naturally occurring human growth factor that is currently approved by the FDA to treat blood cancers. The purpose of this study is to determine whether palifermin can increase CD4 counts in treatment-experienced HIV infected adults. | Antiretroviral therapy (ART) has dramatically improved the clinical outcome for HIV infected adults; however, some people on potent ART experience poor recovery of CD4 counts despite maximum suppression of viral load. Such uncontrolled HIV infection is associated with the reduced ability by the human body to create new... | HIV Infections | Treatment Experienced | null | 4 | arm 1: Participants will receive palifermin placebo injection on Days 1, 2, and 3 arm 2: Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3 arm 3: Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3 arm 4: Participants will receive palifermin 60 mcg/kg injection on Day... | [
2,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: Keratinocyte growth factor administered via injection intervention 2: Keratinocyte growth factor placebo administered via injection | intervention 1: Palifermin intervention 2: Palifermin placebo | 22 | Los Angeles | California | United States | -118.24368 | 34.05223
Los Angeles | California | United States | -118.24368 | 34.05223
Palo Alto | California | United States | -122.14302 | 37.44188
San Diego | California | United States | -117.16472 | 32.71571
Torrance | California | United States | -118.34063 | 33.83585
Mi... | 99 | 0 | 0 | 0 | NCT00376935 | 1COMPLETED | 2008-09-01 | 2006-12-01 | National Institute of Allergy and Infectious Diseases (NIAID) | 0NIH | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 27 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma. | null | Neoplasms Neoplasms by Site Urogenital Neoplasms Genital Neoplasms, Female Uterine Neoplasms Endometrial Neoplasms Cancer of Endometrium Endometrial Cancer Cancer of the Endometrium Endometrium Cancer Neoplasms, Endometrial | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: 900 mg/m2, intravenous (IV), every 21 days, until disease progression | intervention 1: pemetrexed | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 26 | 0 | 0 | 0 | NCT00377520 | 1COMPLETED | 2008-09-01 | 2006-09-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 484 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | A study of patients with type 2 diabetes and inadequate glycemic control on two or more oral antihyperglycemic agents comparing adding insulin lispro mid mixture to the oral antihyperglycemic agents to adding insulin glargine to the oral antihyperglycemic agents. | null | Diabetes Mellitus, Type 2 | diabetes type 2 | null | 2 | arm 1: Insulin lispro mid mixture (MM) up to three times a day (TID) arm 2: Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed. | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks intervention 2: Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks | intervention 1: Insulin lispro mid mixture (MM) intervention 2: Insulin glargine | 25 | Keswick | South Australia | Australia | 138.57459 | -34.94178
Fitzroy | Victoria | Australia | 144.97833 | -37.79839
Fremantle | Western Australia | Australia | 115.74557 | -32.05632
London | Ontario | Canada | -81.23304 | 42.98339
Granby | Quebec | Canada | -72.73243 | 45.40008
Sherbrooke | Quebec | Canada | -71.89908... | 479 | 0 | 0 | 0 | NCT00377858 | 1COMPLETED | 2008-09-01 | 2006-08-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 17 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | This is a Phase II prospective, multicenter study evaluating Progression Free Survival (PFS) after first line treatment with the combination of gemcitabine, docetaxel, and bevacizumab in subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). PFS will be measured from the date of registration (ie, assi... | null | Non-small Cell Lung Cancer | null | 1 | arm 1: Single arm treatment with docetaxel, gemcitabine and bevacizumab | [
0
] | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: docetaxel intervention 2: gemcitabine intervention 3: bevacizumab | 1 | Bridgewater | New Jersey | United States | -74.64815 | 40.60079 | 17 | 0 | 0 | 0 | NCT00378573 | 6TERMINATED | 2008-09-01 | 2007-01-01 | Sanofi | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 781 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate (MF) /formoterol fumarate (F)\[MF/F\] metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind Treatment Period, subjects will receive open-... | null | Asthma | null | 4 | arm 1: None arm 2: None arm 3: None arm 4: None | [
0,
0,
0,
2
] | 4 | [
0,
0,
0,
0
] | intervention 1: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks intervention 2: MF 200 mcg via metered dose inhaler twice daily for 26 weeks intervention 3: F via metered dose inhaler 10 mcg twice a day for 26 weeks intervention 4: Placebo metered dose inhaler twice a day for 26 weeks | intervention 1: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID intervention 2: Mometasone furoate MDI (MF MDI) 200 mcg intervention 3: formoterol fumarate 10 mcg intervention 4: Placebo | 0 | null | 1,765 | 0 | 0 | 0 | NCT00383240 | 1COMPLETED | 2008-09-01 | 2006-09-01 | Organon and Co | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 339 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine (placebo that contains no active ingredient) can help the central neuropathic pain patients experience as a result of multiple sclerosis. This type of pain "central neuropathic pain" is described as shooting, stabbing, burn... | GW has shown in phase II and III studies that Sativex has analgesic properties that are effective in relieving neuropathic pain. These studies suggested that Sativex is well tolerated and may also improve sleep and quality of life. GW is conducting this study to further demonstrate these effects. | Multiple Sclerosis | Central Neuropathic Pain | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.
Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg. intervention 2: Containing colourants and exci... | intervention 1: Sativex intervention 2: Placebo | 6 | Calgary | Alberta | Canada | -114.08529 | 51.05011
Vancouver | British Columbia | Canada | -123.11934 | 49.24966
Halifax | Nova Scotia | Canada | -63.57688 | 44.64269
London | Ontario | Canada | -81.23304 | 42.98339
Ottawa | Ontario | Canada | -75.69812 | 45.41117
Montreal | Quebec | Canada | -73.58781 | 45.50884 | 339 | 0 | 0 | 0 | NCT00391079 | 1COMPLETED | 2008-09-01 | 2006-09-01 | GW Pharmaceuticals Ltd | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 1,683 | NON_RANDOMIZED | SINGLE_GROUP | 1PREVENTION | 0NONE | true | 1FEMALE | false | This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product. | null | Contraception | Contraception | null | 1 | arm 1: Norethindrone/Ethinyl Estradiol | [
0
] | 1 | [
0
] | intervention 1: one tablet per day | intervention 1: Norethindrone acetate/ethinyl estradiol | 66 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Phoenix | Arizona | United States | -112.07404 | 33.44838
Phoenix | Arizona | United States | -112.07404 | 33.44838
Phoenix | Arizona | United States | -112.07404 | 33.44838
Tempe | Arizona | United States | -111.90931 | 33.41477
Tempe | Arizona | United States ... | 1,660 | 0 | 0 | 0 | NCT00391807 | 1COMPLETED | 2008-09-01 | 2006-11-01 | Warner Chilcott | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 53 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | The primary objective of the trial is to estimate the activity of BMS-354825 (Dasatinib) in de novo adult Ph+ ALL patients in terms of hematological complete remission (HCR) rate. | This open label phase II study of Dasatinib will enroll adult de novo Ph+ ALL patients. A minimum of 48 cases will be required to complete the study. Accrual is expected to be completed in 18 months. The study will be considered completed for patients in HCR after completion of a total of 12 weeks of treatment. After c... | Lymphoblastic Leukemia, Acute | Ph+ Acute Lymphoblastic Leukaemia Dasatinib targeted therapy Patients with Ph positive and or BCR ABL positive ALL | null | 0 | null | null | 1 | [
0
] | intervention 1: None | intervention 1: Dasatinib | 36 | Arezzo | Arezzo | Italy | 11.88068 | 43.46276
Bari | Bari | Italy | 16.86982 | 41.12066
Bologna | Bologna | Italy | 11.33875 | 44.49381
Brescia | Brescia | Italy | 10.21472 | 45.53558
Brindisi | Brindisi | Italy | 17.93607 | 40.63215
Cagliari | Cagliari | Italy | 9.11917 | 39.23054
Catania | Catania | Italy | 15.07041 ... | 53 | 0 | 0 | 0 | NCT00391989 | 1COMPLETED | 2008-09-01 | 2006-09-01 | Gruppo Italiano Malattie EMatologiche dell'Adulto | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 44 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The combination of capecitabine and oxaliplatin as 'backbone' regimen, adding a newer biologic agent, cetuximab, is a reasonable strategy of further chemotherapy development in advanced gastric cancer, which is the investigators study rationale. | There is presently no chemotherapy regimen considered to be the global standard of care for patients with AGC, and there is still a need for new agents and/or regimens to improve the efficacy and safety of chemotherapy in advanced stomach cancers.
The combination of 5-fluorouracil plus cisplatin (FP) has been widely u... | Gastric Cancer | gastric cancer chemotherapy cetuximab capecitabine oxaliplatin | null | 1 | arm 1: Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m... | [
0
] | 1 | [
0
] | intervention 1: Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance ... | intervention 1: Capecitabine, Oxaliplatin, Cetuximab | 3 | Seoul | N/A | South Korea | 126.9784 | 37.566
Seoul | N/A | South Korea | 126.9784 | 37.566
Seoul | N/A | South Korea | 126.9784 | 37.566 | 44 | 0 | 0 | 0 | NCT00398398 | 1COMPLETED | 2008-09-01 | 2006-11-01 | Asan Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 312 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | null | Primary objective: to assess the efficacy of pramipexole given two times daily compared to placebo.
Secondary objectives: to assess the effects of pramipexole on mood, cognition, fatigue, impulse control, daytime sleepiness and nighttime sleep compared to placebo; to compare the tolerability among the treatment groups... | null | Parkinson Disease | null | 4 | arm 1: None arm 2: Pramipexole 0.5 mg tid (three times a day) arm 3: Pramipexole 0.5 mg bid (bis in die (two times a day)) arm 4: Pramipexole 0.75 mg bid (bis in die (two times a day)) | [
5,
5,
5,
5
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: Pramipexole intervention 2: Placebo | 39 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Little Rock | Arkansas | United States | -92.28959 | 34.74648
Fountain Valley | California | United States | -117.95367 | 33.70918
La Jolla | California | United States | -117.2742 | 32.84727
Oxnard | California | United States | -119.17705 | 34.1975
Sacramento ... | 311 | 0 | 0 | 0 | NCT00402233 | 1COMPLETED | 2008-09-01 | 2006-11-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 34 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients. This study will assess if a switch from MMF to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI and/or health-related quality of life in liver transplant recipient... | null | Liver Transplantation | Liver transplantation, mycophenolate, GI problems, Quality of Life | null | 1 | arm 1: Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg. | [
0
] | 1 | [
0
] | intervention 1: experimental | intervention 1: Enteric-coated Mycophenolate sodium (EC-MPS) | 1 | Nuremberg | N/A | Germany | 11.07752 | 49.45421 | 34 | 0 | 0 | 0 | NCT00405652 | 1COMPLETED | 2008-09-01 | 2007-01-01 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 26 | RANDOMIZED | FACTORIAL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with keta... | This research proposal will investigate a glutamate-modulating agent, riluzole, in treatment-resistant patients who exhibit an acute, sustained response to a single dose of intravenous (IV) racemic ketamine. Fifty ketamine-responders will be randomized to riluzole or placebo in a 4-week, randomized, double-blind, conti... | Major Depression | null | 2 | arm 1: Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Re... | [
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: anticonvulsant medication intervention 2: subanesthetic dose of NMDAR antagonist intervention 3: glutamate release inhibitor | intervention 1: Lamotrigine intervention 2: Ketamine intervention 3: Riluzole | 1 | New York | New York | United States | -74.00597 | 40.71427 | 66 | 0 | 0 | 0 | NCT00419003 | 1COMPLETED | 2008-09-01 | 2006-12-01 | Baylor College of Medicine | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 24 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | To assess the efficacy and safety of Etanercept in patients with spondylarthropathy and refractory heel enthesitis. | null | Spondylarthropathies, Enthesitis | Refractory Heel Enthesitis in Spondylarthropathy Spondylarthropathy Refractory Heel Enthesitis | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 2 | [
0,
10
] | intervention 1: 50 mg injection once weekly intervention 2: placebo | intervention 1: Etanercept intervention 2: Placebo | 15 | Arles | N/A | France | 4.63031 | 43.67681
Avignon | N/A | France | 4.80892 | 43.94834
Bordeaux | N/A | France | -0.5805 | 44.84044
Grenoble | N/A | France | 5.71479 | 45.17869
Montpellier | N/A | France | 3.87635 | 43.61093
Nice | N/A | France | 7.26608 | 43.70313
Orléans | N/A | France | 1.90389 | 47.90289
Paris (Bich... | 24 | 0 | 0 | 0 | NCT00420303 | 1COMPLETED | 2008-09-01 | 2007-01-01 | Wyeth is now a wholly owned subsidiary of Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 92 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 1FEMALE | false | The main purpose of this study is to compare the effects of treatment of two different formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with prehypertension. | This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial. | Postmenopause Hypertension Pre-Hypertension | Pre-Hypertension in Postmenopausal Women | null | 3 | arm 1: 0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects) arm 2: 2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects) arm 3: 1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 w... | [
0,
0,
1
] | 3 | [
0,
0,
0
] | intervention 1: SH K 00641 A -Active study medication encapsulated tablet intervention 2: SH K 00641 B - Active study medication encapsulated tablet intervention 3: Active control encapsulated tablet | intervention 1: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891) intervention 2: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891) intervention 3: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM) | 9 | Greenbrae | California | United States | -122.5247 | 37.94854
San Diego | California | United States | -117.16472 | 32.71571
Daytona Beach | Florida | United States | -81.02283 | 29.21081
Miami | Florida | United States | -80.19366 | 25.77427
Paw Paw | Michigan | United States | -85.89112 | 42.21782
Las Vegas | Nevada ... | 90 | 0 | 0 | 0 | NCT00420342 | 1COMPLETED | 2008-09-01 | 2007-01-01 | Bayer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 121 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The study will evaluate the effectiveness and safety of multiple dosing regimens of IV conivaptan in subjects with euvolemic or hypervolemic hyponatremia | null | Hyponatremia Euvolemia Hypervolemia | Hyponatremia Euvolemia Hypervolemia Conivaptan Vaprisol® YM087 | null | 4 | arm 1: Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule arm 2: Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule arm 3: Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag arm 4: Conivaptan loading dose (20mg) + 20mg/day continuous in... | [
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: ampoule or premix bag intervention 2: ampoule or premix bag | intervention 1: Conivaptan intervention 2: placebo | 18 | Charleston | South Carolina | United States | -79.93275 | 32.77632
Bangalore | N/A | India | 77.59369 | 12.97194
Bangalore | N/A | India | 77.59369 | 12.97194
Bhopal | N/A | India | 77.40289 | 23.25469
Hyderabaad | N/A | India | N/A | N/A
Karnāl | N/A | India | 76.98448 | 29.69197
Afula | N/A | Israel | 35.2892 | 32.60... | 117 | 0 | 0 | 0 | NCT00435591 | 1COMPLETED | 2008-09-01 | 2007-01-01 | Cumberland Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 32 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | Skin photoaging or skin photodamage were terms used to describe the change in the structure, function and appearance of skin caused by prolonged and repeated exposure to sunlight or other ultraviolet light sources.
The visible effects of skin photodamage were fine lines, skin sagging, skin roughness, liver spots and a... | Different application times of the study treatment were being investigated. | Photoaged Skin | PDT Photoaging Galderma | null | 3 | arm 1: Participants were topically treated with 160 milligrams per gram (mg/g) Metvix cream on one half-face or Metvix vehicle cream on the other half-face for 1 hour at Baseline, Weeks 4 and 8. The target area was then exposed to red light \[using a large-field light emitting diode (LED) light source: Aktilite 128 lam... | [
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: Participants were treated with topical administration of Metvix cream. intervention 2: Participants were treated with topical administration of Metvix Vehicle cream. | intervention 1: Metvix Cream 160 mg/g intervention 2: Metvix Vehicle Group | 3 | Madrid | N/A | Spain | -3.70256 | 40.4165
London | N/A | United Kingdom | -0.12574 | 51.50853
Manchester | N/A | United Kingdom | -2.23743 | 53.48095 | 32 | 0 | 0 | 0 | NCT00437320 | 1COMPLETED | 2008-09-01 | 2007-04-18 | Galderma R&D | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 456 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax malaria. | This is a multi-centre, randomised, double-blind, double-dummy, parallel-group, non-inferiority study comparing the efficacy and safety of the fixed combination of pyronaridine/artesunate (ie, PP/AS \[PA\]) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute uncomplicated P. vivax ma... | Malaria | P vivax malaria artemisinin based combination therapy (ACT) antimalarial pyronaridine artesunate (Pyramax) | null | 2 | arm 1: The tablet strength is 180:60 mg oral PA plus chloroquine-placebo. Depending on their body weight, patients receive 1 to 4 tablets once a day, for 3 days. The actual dose-level range covered by this regimen is 7.2: 2.4 mg/kg to 13.8:4.6 mg/kg pyronaridine artesunate. arm 2: The tablet strength is 155 mg oral chl... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: Pyronaridine artesunate intervention 2: Chloroquine | 5 | Pailin | Pailin | Cambodia | 102.60928 | 12.84895
Mangalore | N/A | India | 74.85603 | 12.91723
Maumere | Nusa Tenggara Timur | Indonesia | 122.2111 | -8.6199
Mae Ramat | Changwat Tak | Thailand | 98.51665 | 16.98403
Mae Sot | Changwat Tak | Thailand | 98.56667 | 16.71667 | 456 | 0 | 0 | 0 | NCT00440999 | 1COMPLETED | 2008-09-01 | 2007-03-01 | Medicines for Malaria Venture | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 60 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | null | To determine efficacy and tolerability of inhaled Formoterol vs nebulized Ipatropioum Bromide plus Fenoterol in cumulative sequential doses in asthmatic children (5-\<12 years) with acute bronchial obstruction attending emergency services | null | Acute Bronchial Obstruction, Asthma | Asthma, Formoterol, Bronchial Obstruction, Children | null | 2 | arm 1: Formoterol (Foradil®) 12 micrograms administered through Aerolizer®. arm 2: Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized. | [
1,
1
] | 2 | [
0,
0
] | intervention 1: 12 micrograms stat (twice if necessary). Inhaled via aerolizer intervention 2: 0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline. | intervention 1: Formoterol fumerate intervention 2: fenoterol/ipratropium bromide | 2 | Caracas | N/A | Venezuela | -66.87919 | 10.48801
Maracaibo | N/A | Venezuela | -71.61089 | 10.64232 | 60 | 0 | 0 | 0 | NCT00460577 | 1COMPLETED | 2008-09-01 | 2007-03-01 | Novartis | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 171 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | null | This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age | null | Bacterial Conjunctivitis | null | 2 | arm 1: None arm 2: None | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Day 1-6 = 1 drop of study medication three times a day intervention 2: Day 1-6 = 1 drop of study medication three times a day | intervention 1: gatifloxacin intervention 2: moxifloxacin 0.5% eye drops | 2 | Sacramento | California | United States | -121.4944 | 38.58157
Whitby | Ontario | Canada | -78.93287 | 43.88342 | 170 | 0 | 0 | 0 | NCT00464438 | 1COMPLETED | 2008-09-01 | 2007-06-01 | Allergan | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 34 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killin... | OBJECTIVES:
Primary
* Determine the overall response rate, response duration, and frequency of progression-free survival at 6 months in patients with stage IV melanoma treated with erlotinib hydrochloride and bevacizumab.
* Determine objective responses in patients treated with this regimen.
Secondary
* Determine t... | Melanoma | stage IV melanoma recurrent melanoma | null | 1 | arm 1: Tarceva and Avastin:
* Tarceva: 150mg PO, days 1-28
* Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course | [
0
] | 7 | [
2,
0,
6,
6,
10,
10,
3
] | intervention 1: 10mg/kg, slow IV infusion, Days 1 and 14 intervention 2: 150mg PO qd intervention 3: Targeting multiple genetic aberrations in isolated tumor cells. intervention 4: gene expression analysis intervention 5: immunologic technique intervention 6: laboratory biomarker analysis intervention 7: biopsy | intervention 1: bevacizumab intervention 2: erlotinib hydrochloride intervention 3: fluorescence in situ hybridization intervention 4: gene expression analysis intervention 5: immunologic technique intervention 6: laboratory biomarker analysis intervention 7: biopsy | 4 | Nashville | Tennessee | United States | -86.78444 | 36.16589
Nashville | Tennessee | United States | -86.78444 | 36.16589
Nashville | Tennessee | United States | -86.78444 | 36.16589
Nashville | Tennessee | United States | -86.78444 | 36.16589 | 34 | 0 | 0 | 0 | NCT00466687 | 1COMPLETED | 2008-09-01 | 2004-09-01 | Vanderbilt-Ingram Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 12 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | true | The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil. | This is a randomized, double-blind, double-dummy, placebo controlled, inpatient, single-center, parallel group evaluation of the potential for oral donepezil to attenuate cocaine-induced craving. Non-treatment-seeking cocaine-experienced volunteers will receive baseline treatment with intravenous cocaine (30Mg). Forty-... | Cocaine Abuse and Dependence | Acetylcholine Acetylcholinesterase Butyrylcholinesterase Cholinesterase Inhibitor | null | 2 | arm 1: Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil arm 2: Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo. | [
0,
0
] | 2 | [
0,
10
] | intervention 1: This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease. intervention 2: Inactive Comparator with Similar Appearance to Active Medication | intervention 1: Donepezil, 5 mg daily intervention 2: Oral Placebo | 1 | Kansas City | Missouri | United States | -94.57857 | 39.09973 | 24 | 0 | 0 | 0 | NCT00467389 | 1COMPLETED | 2008-09-01 | 2007-02-01 | US Department of Veterans Affairs | 1FED | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 385 | RANDOMIZED | PARALLEL | 1PREVENTION | 2DOUBLE | true | 1FEMALE | false | The purpose of this study is to determine whether the study drug is safe and effective | Acronym is used in result section: suspected/diagnosed (susp/diag) | Neural Tube Defects Contraception Oral Contraceptives (OC) | Healthy women requesting contraception Folic Acid | null | 2 | arm 1: 1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks arm 2: 1 tablet 0.020 mg EE/3.0 mg DRSP \[YAZ\] given orally/daily for 24 days followed by 1 placeb... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: 0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF) intervention 2: 0.020 mg ethinylestradiol with 3.0 mg drospirenone | intervention 1: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate intervention 2: Drospirenone/Ethinylestradiol (Yaz) | 9 | Anaheim | California | United States | -117.9145 | 33.83529
San Diego | California | United States | -117.16472 | 32.71571
Baltimore | Maryland | United States | -76.61219 | 39.29038
New York | New York | United States | -74.00597 | 40.71427
Morrisville | North Carolina | United States | -78.82556 | 35.82348
Winston-Sa... | 379 | 0 | 0 | 0 | NCT00468481 | 1COMPLETED | 2008-09-01 | 2007-04-01 | Bayer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.